Eli Lilly Buys a Seat in Abridge’s Exam Room

Eli Lilly put undisclosed money into Abridge on June 11, 2026, buying a stake in software that already records more than 100 million clinical conversations a year. Abridge CEO and co-founder Dr. Shiv Rao announced the check from the stage at the Times Center in New York. The startup’s written release that day named NVIDIA, Aetna, Cigna, and the American Heart Association, and it did not name Lilly.

That omission is the deal. Lilly is not paying to transcribe visits. It is paying for a seat at the microphone that now drafts the note, the codes, the prior auth file, and, if Rao gets his way, the trial screen.

Lilly Bought a Seat the Newsroom Page Left Blank

Rao told the room Lilly’s money would support evidence-based care and research. After the keynote he was more specific. A “top-of-mind use case” for the partnership, he said, is recruiting for clinical trials. “We’re hoping that will be an opportunity that we would be able to explore.”

We started Abridge to save time, save money, and save lives. This next chapter brings trusted intelligence into the most important moment in medicine: a clinician caring for a patient. By grounding AI in the clinical conversation, Abridge can free clinicians to focus more on the practice of medicine and less on the process, help health systems improve care delivery, align payment with the care actually delivered, and connect patients to evidence and resources that can improve outcomes.

Dr. Shiv Rao, CEO and co-founder of Abridge, June 11, 2026 keynote

The AI-native clinician intelligence platform Abridge unveiled that morning is the product wrap around that hope. The Pittsburgh firm, founded in 2018 by Rao, a cardiologist who still practices at UPMC, has spent eight years turning doctor-patient talk into a billable note. Lilly’s check arrives after a $250 million Series D in February 2025 that valued Abridge at $2.75 billion, a $300 million Series E in June 2025 that lifted the price to $5.3 billion, and a $316 million Series E extension in April 2026 at the same valuation. CB Insights logged Lilly’s round as Corporate Minority II. No one published the dollars.

THE SCALE ABRIDGE TOOK ON STAGE

• Health systems: Live at more than 300, from community clinics to large academic centers, with more added weekly.
• Visit volume: More than 100 million clinical conversations a year, the figure Abridge also used in an August hiring post.
• Patient reach: Partner organizations collectively care for more than 250 million patients.
• Price tag: $5.3 billion after the April 2026 extension; Lilly’s slice of that cap table was not disclosed.

Lilly spent $13.3 billion on research and development in 2025. Amy Davis, who leads the company’s clinical development tech agenda, has already described AI as a way to match the right patients to the right studies. Putting money into the ambient mic is a shorter path to that match than waiting for a coordinator to read a chart. It is also a different wager from the $600 million AI drug pact other pharma groups have signed in the lab this year.

What the Platform Does Once the Mic Is On

Abridge’s pitch is no longer a scribe. Before the visit, the software drafts a pre-round note for inpatients from emergency, nursing, lab, and imaging text, and a history of present illness for outpatients from prior talks. During the visit it suggests topics, answers evidence questions without a tab switch, and captures speech. After the visit it produces notes, flowsheets, patient summaries, billing codes, and orders for a human to edit in the record.

WHAT ONE VISIT IS NOW ASKED TO TRIGGER

The table is the product strategy. A better note has a ceiling. A note that also feeds payment and research has five buyers for one recording.

Notes and Codes From the Same Sentence

Abridge said in 2025 that a contextual reasoning engine would write billable notes at the point of care, attacking the lag between a visit and a clean claim. The June platform pushes that further: chronic conditions and complexity are supposed to be captured at the specificity payers will pay for, because the source is the talk, not a chart completed weeks later. AHIMA, the coding association, is being brought in so those outputs can be checked the way professional coders would check them, across fee-for-service and value-based contracts.

Reid Health put a number on the inpatient side. Misti Foust-Cofield, vice president and chief nursing officer, said Abridge helped cut the nursing vacancy rate from 18% to 8.6% with no contract staff, and cut incidental overtime 70% on teams that use it. Retraining a single nurse, she said, costs nearly $100,000. That is the burden case Abridge still leads with, even as Lilly and the plans pull the same audio downstream.

An Alzheimer’s Flag at the Bedside

The life sciences section of the release is careful on paper. Collaborations, it says, will run with governance, consent, security, and institutional control. The worked example is Alzheimer’s disease, where biomarkers and risk can show up years before a diagnosis. The software is supposed to compare guidance with the record and the live talk, then suggest whether trial screening is worth raising. Depending on what is already in the chart, it can start that path from the room.

Rao’s after-show comment was less polished than that paragraph. The Lilly relationship is still something Abridge hopes to explore. The architecture is up. The enrollment is not.

Cigna, Aetna, and the Claims Clock

Payers did not send a press quote. They sent executives. The keynote put insurer and health-system operators on the same risers to talk about collapsing the weeks between a visit and a paid claim.

WHO STOOD ON THE NEW YORK STAGE

• Aetna: Dr. Ben Kornitzer, chief medical officer, with Johns Hopkins Health System CIO Deanna Hanisch on value-based care and care gaps in the room.
• Cigna Healthcare: CIO Madhu Nutakki, with Emory Healthcare CEO Dr. Joon Lee on claims reconciliation in real time.
• Northwestern Medicine: CIO Doug King, announcing an enterprise rollout across hospitals and care settings in Chicago.
• Availity, offstage but live: The January 12, 2026 pact to ground real-time prior authorization work in the same conversation, using Availity’s FHIR-native utilization management stack.

Availity connects over 95% of payers, more than 3 million providers, and over 2,000 trading partners. Russ Thomas, its CEO, said the firm has been building APIs that drop clinical policy logic into provider workflows. Abridge’s job is to make the visit itself the packet: gap alerts while the patient is still talking, then a cleaner authorization file so fewer cases bounce into peer-to-peer review.

Highmark Health started down this road in August 2025, co-designing point-of-care prior auth with Abridge at Allegheny Health Network offices and hospitals. The January Availity deal was the scale play. June was the rebrand: payment alignment as a core module, not a side experiment. Dr. Joon Lee put the political point in hospital language.

The future cannot be providers and insurers using increasingly sophisticated tools to argue over the record after care has already been delivered. We need shared, trusted infrastructure that helps both sides determine the right payment in real time, reduces unnecessary administrative burden, and ensures more of every healthcare dollar goes where it belongs: to patients and the people caring for them.

Dr. Joon Lee, chief executive officer, Emory Healthcare, Abridge keynote

Shared infrastructure sounds like peace. It is also a new control point. If the note, the code, and the auth request are generated together, the vendor that sits in the room can shape what both sides treat as the true record.

How NVIDIA Fits the Exam-Room Model

NVIDIA was the partner the newsroom page was willing to print. NVentures already sat on the cap table. On June 11 the two said they would train a foundation model on clinical conversations rather than adapt a general chatbot, using de-identified data through pre-, mid-, and post-training on Blackwell hardware, built on the Nemotron open model family so weights and training data stay inspectable. Kimberly Powell, NVIDIA’s vice president of healthcare, said Nemotron was “the open frontier model created exactly for this moment.” Rao said Abridge will keep mixing its own models with labs such as OpenAI and Anthropic, and will distill those models for the jobs it actually ships.

The keynote, later posted in full by Abridge, is the hour-long version of that argument, with the Lilly stake as its own chapter.

Menlo Ventures, in a fall 2025 look at the category, put Abridge at about 30% of a $600 million ambient scribe market, just behind Microsoft at 33%. Brian Wright, PitchBook’s lead healthcare analyst, told an interviewer after the keynote that electronic-record vendors are the sharpest competitive risk, and that a note-only tool will not hold. Andreas Cleve, CEO of Corti, said coding looks like a cost line even though it produces revenue, which is why scribes are walking into it, and he expected prices for scribes to drop hard within six to eight months of that June conversation.

Lilly’s factory-side AI has not moved at this speed. Drug-discovery and plant models are still the slow half of the story, the bind in which pharma AI stays stuck in pilot while obesity-drug demand runs hot. The exam-room check is the faster chip: it does not need a new molecule. It needs the next eligible patient, and the next paid claim.

Trial Flags Do Not Fill Screening Slots

Abridge’s own account later spelled out the miss it wants to close. A clinician sees someone who might fit a study and never hears the study exists, because care systems and recruitment systems do not talk.

A clinician sees a patient who might be a perfect fit for a study that could change their life. The clinician doesn’t know the trial exists because the systems we use for patient care and clinical trial recruitment don’t talk to each other. The match never gets made.

The new… pic.twitter.com/R4c2UsVGsu

— Abridge (@AbridgeHQ) July 1, 2026

Moe Alsumidaie, a trial-operations editor who also runs research shops that work with sites, described the other half of that miss. Identification is the easy layer. A coordinator can be handed a long list of names the model liked and still have two open screening slots, a pharmacy that needs 72 hours, and an IRB amendment in flight. Sites in his network spend days reconciling sponsor lists against the live protocol, and a large share of those names fail on the first pass for reasons the model never saw: an age window the sponsor already changed, a drug the transcript did not flag, a diagnosis captured halfway.

If a flag leads to a phone call, that call is a recruitment contact. Under FDA rules on electronic consent, a new way of finding or approaching patients can force an IRB look at the materials. Most sites do not have a template for “ambient documentation system referred this person.” Until they write one, the first flagged patient is not a win. It is a pause.

WHAT WE KNOW

• The check: Lilly made a strategic investment, amount undisclosed, announced by Rao on June 11, 2026.
• The use case: Rao called trial recruiting the top-of-mind use, and the release uses Alzheimer’s as the screening example.
• The consent line: Abridge says life-sciences work will run with governance, consent, security, and institutional control.
• The FDA overlay: Changing how patients are identified or approached can pull in electronic informed consent guidance and an IRB review of recruitment language.

WHAT IS UNCONFIRMED

• Dollar figure: No filing or company note has published what Lilly paid.
• Live enrollment: There is no public count of patients actually screened or randomized through the Abridge flag.
• IRB templates: No standard language has been published for ambient-AI recruitment contacts.
• Data use at Lilly: The drugmaker has not said what conversation-derived signals it will receive, or on what delay.

Consent is already thin in the ambient layer. Mental-health visits recorded for notes have drawn complaints that patients are asked to agree without a clear map of storage, retention, or access. Routing that same audio toward a claim file and a trial list makes the form harder to defend, not easier. Abridge’s release repeats “appropriate consent.” It does not publish the script.

Epic Still Owns the Rails Abridge Rides

The June event was also a warning shot at the record vendors. Abridge is deeply tied into Epic, Oracle Health, and athenahealth. Epic’s own ambient tools, and Microsoft’s Nuance line, sit on the same floors. Abridge cannot buy its way off those rails, and it cannot acquire Epic.

THE BINDS THAT STILL SIT UNDER THE $5.3 BILLION PRICE

• Horizontal rush: On August 17, 2026, Rao opened context-aware decision support to every clinician across more than 300 partner systems, including people who do not use the scribe, a move timed to Epic’s user meeting.
• Wedge math: A cleaner note has diminishing returns. Payment, prior auth, CDS, and trial flags are how Abridge tries to become harder to rip out.
• Room sensors: Smart-room tie-ins with Artisight and hellocare.ai extend the same idea into inpatient cameras and virtual nursing, with UCHealth already pairing hellocare and Abridge.
• Price pressure: Cleve’s June 2026 view was that scribe fees would fall sharply as the category crowded; Wright’s view was that providers will keep fewer vendors, each covering more of the stack.

That August CDS opening is the post-keynote tell. Not every doctor wants a microphone in the room. Abridge still wanted a product those doctors would open, and a reason for a CIO not to add a second evidence chatbot. UpToDate, already in the content library with NEJM and JAMA, becomes infrastructure either way.

Lilly can live with that mess. The drugmaker does not need Abridge to beat Epic. It needs the microphone on during the visit where a biomarker, a missed code, or an eligibility phrase would otherwise die in the hallway. NVIDIA will train the model. Availity will carry the auth. AHIMA will argue about the codes. The hidden party is the one that never took a sentence on the newsroom page, and still bought a seat at the talk.

Frequently Asked Questions

Did Abridge disclose the size of Eli Lilly’s investment?

No. Rao announced a strategic investment on June 11, 2026, with no figure, and CB Insights recorded the round as Corporate Minority II rather than a priced venture series, which is why the $5.3 billion valuation from the April 2026 extension is still the last public mark.

Which record systems does Abridge plug into besides Epic?

The June 11, 2026 release lists deep integration with Epic, Oracle Health, and athenahealth, so the same conversation layer is meant to write back into those three record stacks after a clinician edits and signs.

Can doctors earn education credit inside Abridge decision support?

Yes. Clinicians using Abridge Clinical Decision Support can claim continuing medical education credit through a joint providership with MedicusCME, a hook that sits beside licensed evidence from groups such as the American Diabetes Association and the American Academy of Family Physicians.

How does Abridge show that a generated summary matches the visit?

The company says a feature it calls Linked Evidence maps AI-written summaries back to source data so a clinician can check the output against the underlying talk, a verification step it also cites as the basis for coding and audit work with AHIMA.

Disclaimer: This article is news reporting and analysis of a corporate investment and product launch. It is informational only and is not medical advice, investment advice, or legal advice, and it does not recommend any drug, trial, software contract, or security. Readers who are patients, clinicians, or investors should consult a licensed physician, a health-system compliance officer, or a registered financial adviser before acting on any workflow, consent, or capital decision described here. Figures, partnership statuses, and product claims reflect company statements and third-party datasets as dated in the piece and may change as Abridge, Lilly, or regulators update them.